Policymakers in Washington, DC, and state capitols are considering measures to address the cost of health care, including prescription drugs, and to address insurance adequacy issues. As debate on these initiatives intensifies, we urge that policymakers consider the needs of people with lymphoma and lymphoma survivors.
As of mid-2022, there are a number of treatments for COVID-19 that have been either approved by the FDA or have been authorized for emergency use (EUA).
FDA announced it has approved the use of tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
The Lymphoma Scientific Research Mentoring Program (LSRMP) is a first-of-its-kind education and mentoring program for junior scientists who wish to focus on lymphoma clinical and laboratory/translational research.
After 20 years of living with lymphoma, Lois Rosenblum knows firsthand the importance of a strong support system and advocating
for your health. Following an initial diagnosis of follicular lymphoma in 2002 and several disease transformations since then, she’s passionate about supporting the work that the Lymphoma Research Foundation (LRF) does to power cutting-edge research to treat and defeat lymphoma.